FRI0233 THE RETENTION RATES OF ABATACEPT IN ELDERLY RA PATIENTS (65 YEARS AND ABOVE) WHO CANNOT BE TREATED WITH METHOTREXATE: COMPARISON WITH ETANERCEPT AND TOCILIZUMAB; A SINGLE-CENTER, RETROSPECTIVE, CASE-CONTROL STUDY
E. Kikuchi, N. Aoki, T. Yoshioka, T. Okai. Center for Rheumatology and Joint Surgery, Kawakita General Hospital, Tokyo, Japan Background: There are many elderly rheumatoid arthritis (RA) patients who cannot be treated with methotrexate (MTX) for many reasons, but data about the therapeutic strategies by biologic agents for the patients are insufficient. Objectives: To analyze the retention rate of abatacept in elderly patients with RA who cannot be treated with MTX. Methods: Data were retrospectively collected from the medical records of patients with rheumatoid arthritis at our center. Abatacept (ABT), etanercept (ETN), or tocilizumab (TCZ) was administered to 68 elderly RA patients who could not be treated with MTX. We analyzed the retention rate of each group by Kaplan-Meier curves and the log-rank test. The primary end point was the 24-month retention rate of the biologics without discontinuation due to adverse events, loss or primary lack of effectiveness. Results: In the ABT group (26 cases: a mean age of 77.8±6.3 years, ACPA positive 92.3%, oral steroid use 34.6%), the cumulative retention rates for both 12 and 24 months were 0.699. In the ETN group (26 cases: a mean age of 75.8±5.1 years, ACPA positive 92.0%, oral steroid use 73.1%), the cumulative retention rates for 12 and 24 months were 0.450 and 0.315, respectively. In the TCZ group (16 cases: a mean age of 73.7±5.6 years, ACPA positive 87.5%, oral steroid use 56.3%), the cumulative retention rates for 12 and 24 months were 0.433 and 0.325, respectively. There was a significant difference in the retention rates between ABT groups and the other two groups [log-rank test, p=0.018 (ABT vs. ETN), 0.047 (ABT vs.
TCZ)]. There are no significant retention rates between ETN groups and TCZ groups. Three cases (11.5%) in the ABT group were discontinued the biologic agents by hospitalization for severe infection within 24 months. Five cases (19.2%) in the ETN group, six cases (37.5%) in TCZ group were hospitalized for severe infection, respectively. Conclusions: Our data suggested that abatacept can be used for a period longer than etanercept or tocilizumab for elderly RA patients who cannot be treated with methotrexate. Background: In rheumatoid arthritis (RA), the long lasting effect of rituximab (RTX) on B lymphocyte depletion may influence the choice of biologic after RTX failure but there is currently no specific recommendation about the optimal strategy.
Objectives:
We assessed factors which may have influenced the choice of biologic following failure to RTX in RA patients and analysed the effectiveness of these biologics. Methods: A retrospective study of RA patients, who had started a new biologic during the year after RTX discontinuation, was conducted between 2009 and 2016 in 5 French rheumatology centers. We collected at baseline (at the time the biologic was introduced after RTX) and during follow-up (3, 6 and 12 months), data about patients and disease. Characteristics of the patients receiving tocilizumab (TCZ), abatacept (ABA) or anti-TNF following RTX, the EULAR response and retention rate were compared using univariate and multivariate analyses. Results: 152 RA patients (117 women, mean age 56.9±13 years) were analysed. RA duration was 14.3 years .8], mean DAS28 ESR at baseline 4.8±1.3. 57 patients (37.5%) received TCZ, 47 (31%) anti-TNF and 48 (31.2%) ABA following RTX. 87% had received anti-TNF prior to RTX. No significant difference in the biologics prescription profile was noted across centers. At baseline, sex, disease characteristics and activity, use of concomitant DMARDs or prednisone were not different between the 3 groups. There was no difference in the number of cycles or dose of RTX received and the number of previous anti-TNF treatment. Patients receiving ABA were slightly older (59.8 years vs 54 years for TCZ and 57.8 years for anti-TNF, p=0.06). Multimorbidity index (MMI) assessing the number of comorbidities was higher in the group ABA but not significantly (MMI count 2±1.7 for ABA, 1.6±1.5 for TCZ, 1.7±1.4 for anti-TNF, p=0.5). At 3, 6 and 12 months, DAS28ESR was lower in patients with TCZ as compared to those with anti-TNF or ABA (Table) but tender and swollen joint counts did not differ. The EULAR good-or-moderate response rates were similar across groups (Table) . After adjustment on age, sex, disease duration, MMI count, 
